Leadership

We are a mission-driven and multidisciplinary team of physicists, molecular biologists, geneticists, epidemiologists, computer scientists, chemists, clinicians, drug developers, and entrepreneurs focused on the development and application of AI to patient data to radically transform the discovery and development of new drugs, and ultimately change the way we treat and eventually cure diseases.

Colin Hill

Chief Executive Officer and Co-Founder

Bruce Church, PhD

Chief Mathematics Officer and EVP, Research and Early Development 

Joseph F. Donahue

Chief Business Officer 

Alan Kilyk

Chief Financial Officer

Jeanne Latourelle, D.Sc.

Senior Vice President Precision Medicine

Jerome Windsor, PharmD

Senior Vice President of Corporate Development & Product Strategy

Todd Oakland, PhD

Vice President Customer Value & Success

Craig Cinquina, PhD

Vice President of Business Development 

Ken Levine

Vice President People and Culture

Board of Directors

John Maraganore, PhD

Chair of GNS Board of Directors, Venture Partner at ARCH Venture Partners, Venture Advisor at Atlas Ventures, Executive Partner at RTW Investments. Former founding CEO and Director of Alnylam.

Colin Hill

Chief Executive Officer and Co-Founder

Jan Berger, MD, MJ

President & Chief Executive Officer, Health Intelligence Partners, Vice Chair of GNS Board of Directors

Craig Cimini

Vice President of Strategy and Business Development & Cigna Ventures, Cigna

Rob Coppedge

President and Chief Executive Officer, Echo Health Ventures

Timothy Thompson 

Independent Director & Former Chairman and Chief Executive Officer, Aptus Health
 

Adrian Weller, PhD

Senior Research Fellow, University of Cambridge Programme Director, Artificial Intelligence, The Alan Turing Institute

Board Observers

Roberto Barzi

President and Co-Founder and Managing Director, Fort Rock Capital

Joel Krikston

Managing Director Venture Investments/Head of Strategic Innovation Alliances, Merck Global Health Innovation Fund 

David W. Miller, PhD

Operating Partner, GHO Capital

Scott Musch

Vice President, Corporate Development, Cambia Health

Samantha Palmer

Managing Director, Amgen Ventures

Shin Serizawa

Director, IT & Communication Business Dept., Mitsui & Co, (U.S.A.) Inc.

Vijay Venkatesan

Vice President and Chief Analytics Officer, Horizon BCBSNJ

Advisors

Tom Daniel 

Venture Partner at ARCH, former President of R&D at Celgene

Jean-Michel Gris

President of Hengenix Biotech and Head of Research for Henlius Biotech 

Ole Isacson, PhD

Professor Neurology and Neuroscience Harvard Medical School, Massachusetts General Hospital, McLean Hospital, HSCI

Jonathan Keats

Lead GNS Advisor for Multiple Myeloma, Lead MM Researcher at Tgen / City of Hope

William Klitgaard

Former President LabCorp’s Enlighten Health

Peter Neupert

Lead Director at Adaptive and LabCorp, former Corporate Vice President at Microsoft and Founder and Chief Executive Officer of drugstore.com

Lee Newcomer 

Board member of Myriad Genetics and CellWorks
Former Senior Vice President, Oncology and Genetics, and Chief Medical Officer at UnitedHealth Group

Ravi B. Parikh, MD, MPP, FACP

GNS Chief Oncology Advisor
Oncologist and Faculty Member at University of Pennsylvania & Board of Directors at Coalition to Transform Advanced Care

Phil Rowlands, PhD

Independent Consultant, Oncology Drug Development
Former head of Oncology R&D at Takeda
Former VP, Asset Team Leader, Oncology Business Unit at Pfizer

Our Investors